Chronic low grade inflammation as a shared pathway in modern disease

One of the more useful shifts in medicine over the past three decades has been the recognition that persistent low grade inflammation is not an incidental finding in chronic disease. It is frequently part of the mechanism. This is now mainstream cardiology, mainstream endocrinology and mainstream rheumatology, though the three fields tend to discuss it separately.

For clinicians managing patients who sit across several of those boundaries at once, the overlap is not academic. It changes what you measure and what you address.

What low grade inflammation is, and is not

Acute inflammation is a coordinated, self limiting response to injury or infection. It resolves. The state under discussion here is different: a persistent, modest elevation in inflammatory signalling that produces no fever and no obvious inflamed tissue, but continues for years.

It is measurable, imperfectly, through markers such as high sensitivity C reactive protein. It is not a diagnosis in itself, and elevated markers have many causes including recent infection, obesity, smoking and poor sleep. Treating a number rather than a patient is a mistake here as everywhere.

Where the pathways converge

Several mechanisms recur across conditions that are managed by different specialties.

• Adipose tissue as an endocrine and immune organ, particularly visceral fat, which secretes inflammatory mediators rather than simply storing energy
• Insulin resistance, which both contributes to and is worsened by inflammatory signalling, producing a self reinforcing loop
• Intestinal barrier function and its influence on systemic immune activation
• Sleep restriction and circadian disruption, which measurably alter inflammatory markers within days in controlled studies
• Chronic psychological stress, acting through neuroendocrine pathways with well described immune consequences

Read together, these explain a pattern most clinicians recognise: the patient with central adiposity, borderline glycaemia, poor sleep, aching joints and low mood is not presenting with five unrelated problems.

What it means for practice

The practical implication is not that inflammation should be suppressed pharmacologically in every patient. It is that the modifiable inputs into this shared pathway deserve to be treated as clinical work rather than as lifestyle advice appended to the end of a consultation.

Sleep, visceral adiposity, physical activity, dietary pattern, oral health, untreated infections and psychological load are all legitimate clinical targets with plausible mechanistic links to the same pathway. They are also, notably, the interventions least likely to be reimbursed and most likely to be delegated away.

Where the evidence is strong and where it is not

The association between chronic inflammation and cardiometabolic outcomes is robust and replicated. The evidence that specific anti inflammatory interventions improve outcomes is mixed and highly dependent on the intervention and the population. The evidence for many commercially promoted anti inflammatory protocols and supplements is weak.

Clinicians working in this area carry a particular responsibility to hold those three tiers apart in their own minds and in their communication with patients. The mechanism being plausible is not the same as the intervention being proven, and patients are entitled to know which one they are being offered.

This article is written for education and professional discussion. It is not medical advice and it is not a substitute for consultation with a clinician who knows your history. Nothing here should be used as a reason to stop or alter prescribed treatment without the involvement of the doctor who prescribed it.